July 12, 2010 09:09 ET

New Report Forecasts HIV/AIDS Market to Reach $13.7 Billion by 2016

ROCKVILLE, MD--(Marketwire - July 12, 2010) - has announced the addition of GlobalData's new report "HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016," to their collection of Diseases & Conditions market reports. For more information, visit

GlobalData's report, "HIV/AIDS - Pipeline Assessment and Market Forecasts to 2016" provides an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was worth $12 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% for the next seven years to reach $13.7 billion by 2016. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has however succeeded in achieving near zero levels of HIV in infected people. Increased uptake of HAART and increasing awareness (which leads to increased treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 261 molecules currently in development for various disease segments.

Topics covered in the report include...

  • Annualized global HIV/AIDS market revenues data from 2001 to 2009, forecast for seven years to 2016.
  • Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include HIV vaccines, Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), CCR5 receptor antagonists, HIV integrase inhibitors, Nucleoside analogues, Viral entry inhibitors, Maturation inhibitors and Fusion Inhibitors.
  • Analysis of the current and future market competition in the global HIV/AIDS market. The key market players covered Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • A strategic competitor assessment, market characterization, unmet needs and implications for the future HIV/AIDS market.

For more information visit

Contact Information